1. Home
  2. MNTK vs FULC Comparison

MNTK vs FULC Comparison

Compare MNTK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Montauk Renewables Inc.

MNTK

Montauk Renewables Inc.

BUY

Current Price

$2.60

Market Cap

267.6M

Sector

Utilities

ML Signal

BUY

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.84

Market Cap

285.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNTK
FULC
Founded
1980
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.6M
285.4M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
MNTK
FULC
Price
$2.60
$3.84
Analyst Decision
Hold
Buy
Analyst Count
2
8
Target Price
$1.80
$16.38
AVG Volume (30 Days)
332.6K
1.1M
Earning Date
05-07-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$176,382,000.00
N/A
Revenue This Year
$18.55
N/A
Revenue Next Year
$12.68
N/A
P/E Ratio
$146.00
N/A
Revenue Growth
0.37
N/A
52 Week Low
$1.07
$2.83
52 Week High
$2.73
$15.74

Technical Indicators

Market Signals
Indicator
MNTK
FULC
Relative Strength Index (RSI) 63.90 49.34
Support Level $1.49 $3.75
Resistance Level $2.73 $3.92
Average True Range (ATR) 0.21 0.06
MACD -0.00 -0.01
Stochastic Oscillator 71.28 36.67

Price Performance

Historical Comparison
MNTK
FULC

About MNTK Montauk Renewables Inc.

Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: